Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on PLETHORA SOLUTIONS HOLDINGS. We currently have 6 research reports from 2 professional analysts.
|09Mar16 08:15||RNS||Scheme becomes Effective|
|08Mar16 16:44||RNS||Court Sanction of Scheme - Replacement|
|08Mar16 15:12||RNS||Scheme becomes Effective|
|08Mar16 07:30||RNS||Suspension - Plethora Solutions Holdings Plc|
|07Mar16 13:36||RNS||Suspension of trading of Shares|
|03Mar16 17:25||RNS||R&D Tax Credit Receipt and Director Dealing|
|02Mar16 12:00||RNS||Result of Shareholder and Court Meetings|
Frequency of research reports
Research reports on
PLETHORA SOLUTIONS HOLDINGS
PLETHORA SOLUTIONS HOLDINGS
01 Sep 15
Servoca*: Acquisition of A+ Teachers (CORP) | Vmoto*: Interim results on track with strong momentum (CORP) | Plethora Solutions*: Interims (CORP) | STM Group*: Making good progress (CORP) | Wolf Minerals: First tungsten concentrate produced (BUY) |Falcon Oil & Gas: Kalala S-1 well result (BUY)
Keep it up
31 Jul 15
Plethora is a specialty pharmaceutical company focused on commercialising PSD502™ (a treatment for male premature ejaculation) with strategic marketing partners and obtaining approval from the US FDA. The product received marketing authorisation from the European Medicines Agency (EMA) in November 2013 and was successfully partnered with Recordati in Europe and a few other territories. On the basis of DCF analysis, we value Plethora Solutions at £86.0m, underpinning our target price of 8.0p/share. Given the current share price, this implies 106.0% upside from current levels with a two-year horizon.
Initiation of coverage
31 Jul 15
‘Traditional headwinds looming large'. The UK Industrials sector has survived, indeed prospered, by focusing on high value added niches and growth markets. Unfortunately, one of these – the Oil & Gas segment – has been hit hard by the collapse in the oil price. Coupled with strong Sterling and weak demand in much of the developed world, the sector faces stiff headwinds for the balance of 2015 and into 2016.
Life Sciences Review - London calling to the faraway biotech: Now a bubble is declared and IPOs hail down
08 Jun 15
Usually this time of year, the who’s who of the Life Sciences’ world have their eyes firmly on the US with the annual meeting of the American Society of Clinical Oncology (ASCO). Chicago becomes a battleground for over 30,000 doctors and scientists jostling with companies vying and hoping to get their clinical data in front of the right people.
20 Apr 17
Although the last two months have seen a broadly neutral performance from the UK healthcare sector compared to a significantly more volatile 6 months prior, we continue to expect macro-events and increased geo-political risk to result in an overall neutral performance from the sector over the next period. However, company specific news is likely to drive a strong outperformance from selected mid-market companies. We retain our neutral sector stance whilst highlighting those we expect to outperform.
Positive top-line results in first iclaprim phase III clinical trial (REVIVE-1)
18 Apr 17
Motif Bio (LSE: MTFB, NASDAQ: MTFB), a late clinical stage antibiotic development company, announced positive results this morning in the first of its two iclaprim phase III clinical trials, REVIVE-1, comparing iclaprim to vancomycin in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Iclaprim, a next-generation antibiotic targeting an underutilised mechanism of action which causes rapid killing of bacteria, is being developed for the treatment of serious and life threatening bacterial infections. On the key primary endpoint in the study, early clinical response at 48-72 hours after drug treatment began, 80.9% of patients on iclaprim achieved a positive response compared to 81.0% of patients on vancomycin, well within the 10% non-inferiority margin required by the FDA. Iclaprim was also shown to be safe and well-tolerated compared to vancomycin. With these positive results from REVIVE-1 we have increased the probability of success for the iclaprim development program from 65% to 75% raising our risk-adjusted NPV for Motif Bio to almost £240m or 122p per share (previously £210m and 107p per share).
N+1 Singer - Small-cap quantitative research - Growth style screen revamp and 10 focus stocks
06 Apr 17
We have reviewed the performance of our consistent growth screen since the previous refresh on 27 September 2016 and revamped the selection parameters to focus more on forecast sales and EPS growth going forward. In the period under review the consistent growth style screen outperformed the small-cap benchmark by c. 6% and underperformed the microcap index by a similar amount. Interestingly, although growth doesn’t always seem to be defensive as might be expected, however it appears right to buy growth on dips caused by or coincident with wider market volatility. In the new forecast growth screen we take a close look at 10 focus stocks. We will monitor performance and refresh it in three to four months time.
N+1 Singer - Sinclair Pharma - EBITDA upgrade for 2017, but lower TP due to warranty claim and costs
19 Apr 17
We have updated product-level forecasts and included the £10m SVB debt facility and £5m warranty claim settlement with Alliance Pharma in our forecasts. The 6.3% upgrade to our FY2017 sales estimate (from £46.0m to £48.9m) brings expected EBITDA profitability forward by one year (to FY2017 from FY2018). We remain positive on the ongoing rollout of Silhouette Instalift® in particular and retain our Buy recommendation. However, higher expected sales & marketing costs and the warranty claim weigh on our valuation: we downgrade our target price from 42p to 37p.
Positive REVIVE-1 Phase III study data
18 Apr 17
Motif Bio (MTFB) has announced positive top-line results from REVIVE-1, its global Phase III study comparing iclaprim to vancomycin in patients with acute bacterial skin and skin structure infections (ABSSSI). Iclaprim achieved the primary endpoint of non inferiority when compared to vancomycin, in both the early time point and test of cure endpoint. Iclaprim offers clinical advantages over existing hospital antibiotics that include the avoidance of renal toxicity, fixed dosage regimen and early response indications. With data from REVIVE-2 due out in H2 2017 we maintain our 125p price target and Buy recommendation.